The provisions of this section shall be null, void, and of no force and effect on and after July 1, 2021.
(1) In this section:
(a) "Anti-epileptic drug" means:
(i) A drug used for the treatment of epilepsy; or
(ii) A drug used to treat or prevent seizures.
(b) "Drug product selection" means the selection of a therapeutically equivalent drug, including a generic version for the prescribed brand, a branded version for the prescribed generic, or a generic version by one (1) manufacturer for a generic version by a different manufacturer.
(c) "Epilepsy" means a neurological condition characterized by recurrent seizures.
(d) "Seizure" means an acute clinical change secondary to a brief disturbance in the electrical activity of the brain.
(2) When a prescriber has specified that a drug is prescribed for the treatment of epilepsy or seizures, pharmacy personnel who perform drug product selections shall:
(a) Notify the prescriber of such drug product selection via facsimile, telephone message or any other appropriate means to the prescriber’s place of business; and
(b) Provide the patient or the patient’s representative with notification of the selection.
(3) Nothing in this section shall delay the dispensing of a valid prescription for an anti-epileptic drug.